Key result
First-in-human implantation of the BVS poly-L-lactic acid everolimus-eluting coronary stent resulted in no adverse events in-hospital or by 1 month.
Case Report (n=1)
No
The first-in-human implantation of a fully bioabsorbable everolimus-eluting coronary stent demonstrated initial safety and feasibility with no adverse events at 1 month.
Short-term safety in one case; leaves open need for larger trials to assess durability and comparative outcomes.
The first-in-human fully bioabsorbable drug-eluting stent (BVS poly-L-lactic acid everolimus-eluting coronary stent) implantation was performed at Auckland City Hospital, New Zealand as part of the ABSORB trial. There were no adverse events in-hospital or by 1 month. A stent that supports the vessel when needed, delivers an antiproliferative drug then disappears has theoretical advantages with regard to CT and MRI compatibility, restored vessel vasomotion, and facilitated future percutaneous intervention or surgical grafting to the treated site.
No takes yet. Share an insight, caveat, or question.
Ormiston et al. (2006) conducted a case report in Coronary artery disease (n=1). BVS poly-L-lactic acid everolimus-eluting coronary stent was evaluated on Adverse events in-hospital or by 1 month. First-in-human implantation of the BVS poly-L-lactic acid everolimus-eluting coronary stent resulted in no adverse events in-hospital or by 1 month.